Freenome vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Freenome is a biotech company developing AI-powered multiomics blood tests for early cancer detection; raised $1.1B+ total with Roche as a major investor; signed a $75M exclusive license with Exact Sciences for colorectal cancer;
About
Freenome is a clinical-stage biotechnology company founded in 2014 and headquartered in South San Francisco, California. The company is developing a multiomics blood-based testing platform for the early detection of cancer — combining genomics, proteomics, metabolomics, and epigenomics signals from a single blood draw and applying AI/ML models to distinguish cancer-derived signals from normal biological variation. Its lead program targets colorectal cancer (CRC) screening, aiming to provide a non-invasive alternative to colonoscopy for the millions of Americans who decline or delay guideline-based screening.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.